Schistosoma mansoni is mainly parasitized in the small mesenteric veins, hemorrhoidal plexus, and occasionally in the superior mesenteric veins and intrahepatic portal vessels. The main lesions of schistosomiasis are in the colon and liver, producing egg granulomas and fibrosis, similar to but less severe than schistosomiasis japonica.
CRISPR/Cas9 is a very effective genome-targeted modification system that enables genetic manipulation such as gene masking, targeted insertion and gene repair at specific genomic loci, providing a technological innovation platform for parasite gene function analysis, drug targeting and vaccine molecular screening.
Ace Therapeutics specializes in parasitology and has established a parasite genetic engineering technology platform designed to provide genetic engineering services for a variety of parasitic diseases to clients worldwide. We can provide CRISPR/Cas9 gene editing services for Schistosoma mansoni, laying the foundation for in-depth elucidation of mechanistic studies.
We established the Schistosoma mansoni CRISPR/Cas9 genome modification method, which can effectively perform gene knockout, gene targeted knock-in and replacement, single base editing, gene activation and repression, and gene epistasis modification in Schistosoma mansoni. Based on this, the method was further developed to address the technical needs of multiple gene modifications in the study of Schistosoma mansoni gene function. If you want to know more, you are welcome to consult us.
Applications
Delivery content: experiment report and cell line edited by CRISPR/Cas9 technology
Test fee: please get it through online inquiry.
Ace Therapeutics is a contract service provider focused on parasitology research, providing innovative solutions and technologies for parasite detection, genetic engineering, and drug development. We support global research institutes, universities, and pharmaceutical companies in advancing their research goals.